Peripheral Drug Eluting Balloon Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2033

Description

Persistence Market Research has recently released a comprehensive report on the worldwide market for peripheral drug eluting balloons. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure.

Key Insights:

Peripheral Drug Eluting Balloons Market Size (2024E): USD 948.6Million
Projected Market Value (2033F): USD 1950.5 Million
Global Market Growth Rate (CAGR 2024 to 2033): 8.3%

Peripheral Drug Eluting Balloons Market - Report Scope:

Peripheral drug eluting balloons play a crucial role in the treatment of peripheral artery disease (PAD) by delivering medication directly to the arterial walls to inhibit restenosis and improve blood flow. These balloons are used in various healthcare settings, including hospitals, clinics, and outpatient centers, offering a range of drug formulations and balloon sizes to cater to different patient needs. Market growth is driven by the increasing prevalence of PAD, advancements in balloon technology, and a growing preference for minimally invasive procedures.

Market Growth Drivers:

The global peripheral drug eluting balloons market is propelled by several key factors, including the rising incidence of PAD, which affects millions of people worldwide. The demand for effective treatment options that offer sustained drug delivery and reduced restenosis rates is driving the adoption of drug eluting balloons. Technological advancements, such as the development of next-generation balloons with improved drug coatings and delivery mechanisms, enhance treatment efficacy and patient outcomes. Additionally, the increasing adoption of minimally invasive procedures and favorable reimbursement policies are further contributing to market growth.

Market Restraints:

Despite promising growth prospects, the peripheral drug eluting balloons market faces challenges related to regulatory compliance, high costs, and limited awareness in emerging markets. Stringent regulations governing the approval and use of drug eluting balloons impose significant compliance burdens on manufacturers. The high cost of these devices and associated procedures can also be a barrier to widespread adoption, particularly in regions with limited healthcare budgets. Furthermore, the lack of awareness about PAD and available treatment options in developing countries hinders market penetration.

Market Opportunities:

The peripheral drug eluting balloons market presents significant growth opportunities driven by technological innovations, demographic trends, and expanding healthcare infrastructure. The integration of advanced drug formulations and novel delivery technologies into balloon devices is expected to enhance therapeutic outcomes and broaden the application scope. Increasing investments in healthcare infrastructure, particularly in emerging economies, are anticipated to create new market opportunities. Strategic collaborations, investment in R&D, and the introduction of cost-effective solutions are essential to capitalize on these opportunities and sustain market leadership.

Key Questions Answered in the Report:

What are the primary factors driving the growth of the peripheral drug eluting balloons market globally?
Which drug formulations and applications are driving the adoption of peripheral drug eluting balloons across different healthcare settings?
How are technological advancements reshaping the competitive landscape of the peripheral drug eluting balloons market?
Who are the key players contributing to the peripheral drug eluting balloons market, and what strategies are they employing to maintain market relevance?
What are the emerging trends and future prospects in the global peripheral drug eluting balloons market?

Competitive Intelligence and Business Strategy:

Leading players in the global peripheral drug eluting balloons market, including Medtronic, B. Braun Melsungen AG, and Boston Scientific Corporation, focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest in R&D to develop advanced drug eluting balloon solutions, including devices with enhanced drug coatings and delivery systems, catering to diverse patient needs and clinical requirements. Collaborations with healthcare providers, medical device distributors, and regulatory agencies facilitate market access and promote technology adoption. Moreover, emphasis on clinical research, evidence-based practice, and patient education fosters market growth and enhances patient outcomes in the rapidly evolving peripheral drug eluting balloons landscape.

Key Companies Profiled:

Abbott Laboratories
Boston Scientific Corporation
Cook Medical Inc.
MicroPort Scientific Corporation (Endovastec(TM))
Medtronic Plc.
Cardinal Health, Inc.
B. Braun Melsungen AG
BIOTRONIK SE & Co. KG
Becton, Dickinson and Company
W. L. Gore & Associates Inc.
Getinge AB
Terumo Corp
Kyoto Medical Planning Co Ltd
iVascular S.L.U
AMG International GmbH
ENDOCOR GmbH
Meril Life Sciences Pvt. Ltd.
Nano Therapeutics Pvt Ltd
Koninklijke Philips N.V.
REVA Medical

Key Segments of Peripheral Drug Eluting Balloons Industry Research

Drug Coating:

Paclitaxel Drug Coating
Sirolimus drug Coating

Indication:

Peripheral Arterial Disease
Peripheral Aneurysms
In-Stent Restenosis

Artery Type:

Carotid Arteries
Fem-Pop Arteries
Iliac Arteries
Infrapop Arteries

End User:

Hospitals
Ambulatory Surgical Centers/Outpatients
Cardiac Catheterization Labs

Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa

Product Code: PMRREP27211

1. Executive Summary

1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions

3. Key Market Trends

3.1. Key Trends Impacting the Market
3.2. Drug Coating Innovation / Development Trends

4. Value Added Insights

4.1. Product Adoption/ Usage Analysis, by region
4.2. Regulatory Scenario
4.3. Technology Assessment
4.4. Value Chain Analysis
4.5. Recent Product Approvals and Launches
4.6. Porter's Analysis
4.7. Product USP Analysis

5. Market Background

5.1. Macro-Economic Factors
- 5.1.1. Global GDP Growth Outlook
- 5.1.2. Global Healthcare Outlook
- 5.1.3. Global Peripheral Vascular Devices Market Outlook
5.2. Forecast Factors - Relevance & Impact
- 5.2.1. Growth in Healthcare Spending
- 5.2.2. Growth in Geriatric Population
- 5.2.3. Rising Number of Peripheral Surgeries
- 5.2.4. Technological Advancements
- 5.2.5. Regulatory Landscape
- 5.2.6. Cost of Procedures
- 5.2.7. Product Adoption Rate and Demand
- 5.2.8. Increase in Research and Development
- 5.2.9. Pharmaceutical Industry Consolidation Activities
- 5.2.10. Top Companies' Historical Growth
5.3. Market Dynamics
- 5.3.1. Drivers
- 5.3.2. Restraints
- 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

6.1. COVID-19 and Impact Analysis
- 6.1.1. By Drug Coating
- 6.1.2. By Indication
- 6.1.3. By Artery Type
- 6.1.4. By End User
- 6.1.5. By Region
6.2. 2024 Market Scenario

7. Global Market Demand in Volume (Units) Analysis 2019-2023 and Forecast, 2024-2033

7.1. Historical Market Volume (Units) Analysis, 2019-2023
7.2. Current and Future Market Volume (Units) (Units) Projections, 2024-2033
- 7.2.1. Y-o-Y Growth Trend Analysis

8. Global Market - Pricing Analysis

8.1. Regional Pricing Analysis By Drug Coating
8.2. Pricing Break-up
- 8.2.1. Manufacturer Level Pricing
- 8.2.2. Distributor Level Pricing
8.3. Global Average Pricing Analysis Benchmark
8.4. Pricing Assumptions

9. Global Market Demand (in Value US$ Mn) Analysis 2019-2023 and Forecast, 2024-2033

9.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
9.2. Current and Future Market Value (US$ Mn) Projections, 2024-2033
- 9.2.1. Y-o-Y Growth Trend Analysis
- 9.2.2. Absolute $ Opportunity Analysis
9.3. Revenue Opportunity Scenario

10. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Drug Coating

10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis, by Drug Coating, 2019-2023
10.3. Current and Future Market Size (US$ Mn) and Volume (Units) Analysis and Forecast, by Drug Coating, 2024-2033
- 10.3.1. Paclitaxel Drug Coating
- 10.3.2. Sirolimus drug Coating
- 10.3.3. Others
10.4. Market Attractiveness Analysis, by Drug Coating

11. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Indication

11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Mn) Analysis, By Indication, 2019-2023
11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, by Indication, 2024-2033
- 11.3.1. Peripheral Arterial Disease
- 11.3.2. Peripheral Aneurysms
- 11.3.3. In-Stent Restenosis
- 11.3.4. Others
11.4. Market Attractiveness Analysis, by Indication

12. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Artery Type

12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Mn) Analysis, By Artery Type, 2019-2023
12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, by Artery Type, 2024-2033
- 12.3.1. Carotid Artery
- 12.3.2. Fem-Pop Artery
- 12.3.3. Iliac Artery
- 12.3.4. Infrapop Artery
12.4. Market Attractiveness Analysis, by Artery Type

13. Global Market Analysis 2019-2023 and Forecast 2024-2033, By End User

13.1. Introduction / Key Findings
13.2. Historical Market Size (US$ Mn) Analysis, By End User, 2019-2023
13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, by End User, 2024-2033
- 13.3.1. Hospitals
- 13.3.2. Ambulatory Surgical Centers/Outpatients
- 13.3.3. Cardiac Catheterization Labs
13.4. Market Attractiveness Analysis, by End User

14. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Region

14.1. Introduction
14.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis, by Region, 2019-2023
14.3. Current and Future Market Value (US$ Mn) Volume (Units) Analysis and Forecast, By Region, 2024-2033
- 14.3.1. North America
- 14.3.2. Latin America
- 14.3.3. Europe
- 14.3.4. South Asia
- 14.3.5. East Asia
- 14.3.6. Oceania
- 14.3.7. Middle East and Africa (MEA)
14.4. Market Attractiveness Analysis, by Region

15. North America Market Analysis 2019-2023 and Forecast 2024-2033

15.1. Introduction
15.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis, by Market Taxonomy, 2019-2023
15.3. Current and Future Market Value (US$ Mn) Volume (Units) Analysis and Forecast, by Market Taxonomy, 2024-2033
- 15.3.1. By Country
  - 15.3.1.1. U.S.
  - 15.3.1.2. Canada
- 15.3.2. By Drug Coating
- 15.3.3. By Indication
- 15.3.4. By Artery Type
- 15.3.5. By End User
15.4. Market Attractiveness Analysis
- 15.4.1. By Country
- 15.4.2. By Drug Coating
- 15.4.3. By Indication
- 15.4.4. By Artery Type
- 15.4.5. By End User
15.5. PESTLE Analysis
15.6. Market Trends
15.7. Key Market Participants - Intensity Mapping
15.8. Drivers and Restraints - Impact Analysis
15.9. Country Level Analysis & Forecast
- 15.9.1. U.S. Market Analysis
  - 15.9.1.1. Introduction
  - 15.9.1.2. Market Analysis and Forecast, by Market Taxonomy
    - 15.9.1.2.1. By Drug Coating
    - 15.9.1.2.2. By Indication
    - 15.9.1.2.3. By Artery Type
    - 15.9.1.2.4. By End User
- 15.9.2. Canada Market Analysis
  - 15.9.2.1. Introduction
  - 15.9.2.2. Market Analysis and Forecast, by Market Taxonomy
    - 15.9.2.2.1. By Drug Coating
    - 15.9.2.2.2. By Indication
    - 15.9.2.2.3. By Artery Type
    - 15.9.2.2.4. By End User

16. Latin America Market Analysis 2019-2023 and Forecast 2024-2033

16.1. Introduction
16.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis, by Market Taxonomy, 2019-2023
16.3. Current and Future Market Value (US$ Mn) Volume (Units) Analysis and Forecast, by Market Taxonomy, 2024-2033
- 16.3.1. By Country
  - 16.3.1.1. Mexico
  - 16.3.1.2. Brazil
  - 16.3.1.3. Argentina
  - 16.3.1.4. Rest of Latin America
- 16.3.2. By Drug Coating
- 16.3.3. By Indication
- 16.3.4. By Artery Type
- 16.3.5. By End User
16.4. Market Attractiveness Analysis
- 16.4.1. By Country
- 16.4.2. By Drug Coating
- 16.4.3. By Indication
- 16.4.4. By Artery Type
- 16.4.5. By End User
16.5. PESTLE Analysis
16.6. Market Trends
16.7. Key Market Participants - Intensity Mapping
16.8. Drivers and Restraints - Impact Analysis
16.9. Country Level Analysis & Forecast
- 16.9.1. Mexico Market Analysis
  - 16.9.1.1. Introduction
  - 16.9.1.2. Market Analysis and Forecast, by Market Taxonomy
    - 16.9.1.2.1. By Drug Coating
    - 16.9.1.2.2. By Indication
    - 16.9.1.2.3. By Artery Type
    - 16.9.1.2.4. By End User
- 16.9.2. Brazil Market Analysis
  - 16.9.2.1. Introduction
  - 16.9.2.2. Market Analysis and Forecast, by Market Taxonomy
    - 16.9.2.2.1. By Drug Coating
    - 16.9.2.2.2. By Indication
    - 16.9.2.2.3. By Artery Type
    - 16.9.2.2.4. By End User
- 16.9.3. Argentina Market Analysis
  - 16.9.3.1. Introduction
  - 16.9.3.2. Market Analysis and Forecast, by Market Taxonomy
    - 16.9.3.2.1. By Drug Coating
    - 16.9.3.2.2. By Indication
    - 16.9.3.2.3. By Artery Type
    - 16.9.3.2.4. By End User

17. Europe Market Analysis 2019-2023 and Forecast 2024-2033

17.1. Introduction
17.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis, by Market Taxonomy, 2019-2023
17.3. Current and Future Market Value (US$ Mn) Volume (Units) Analysis and Forecast, by Market Taxonomy, 2024-2033
- 17.3.1. By Country
  - 17.3.1.1. Germany
  - 17.3.1.2. Italy
  - 17.3.1.3. France
  - 17.3.1.4. U.K.
  - 17.3.1.5. Spain
  - 17.3.1.6. BENELUX
  - 17.3.1.7. Russia
  - 17.3.1.8. Nordic Countries
  - 17.3.1.9. Rest of Europe
- 17.3.2. By Drug Coating
- 17.3.3. By Indication
- 17.3.4. By Artery Type
- 17.3.5. By End User
17.4. Market Attractiveness Analysis
- 17.4.1. By Country
- 17.4.2. By Drug Coating
- 17.4.3. By Indication
- 17.4.4. By Artery Type
- 17.4.5. By End User
17.5. PESTLE Analysis
17.6. Market Trends
17.7. Key Market Participants - Intensity Mapping
17.8. Drivers and Restraints - Impact Analysis
17.9. Country Level Analysis & Forecast
- 17.9.1. Germany Market Analysis
  - 17.9.1.1. Introduction
  - 17.9.1.2. Market Analysis and Forecast, by Market Taxonomy
    - 17.9.1.2.1. By Drug Coating
    - 17.9.1.2.2. By Indication
    - 17.9.1.2.3. By Artery Type
    - 17.9.1.2.4. By End User
- 17.9.2. Italy Market Analysis
  - 17.9.2.1. Introduction
  - 17.9.2.2. Market Analysis and Forecast, by Market Taxonomy
    - 17.9.2.2.1. By Drug Coating
    - 17.9.2.2.2. By Indication
    - 17.9.2.2.3. By Artery Type
    - 17.9.2.2.4. By End User
- 17.9.3. France Market Analysis
  - 17.9.3.1. Introduction
  - 17.9.3.2. Market Analysis and Forecast, by Market Taxonomy
    - 17.9.3.2.1. By Drug Coating
    - 17.9.3.2.2. By Indication
    - 17.9.3.2.3. By Artery Type
    - 17.9.3.2.4. By End User
- 17.9.4. U.K. Market Analysis
  - 17.9.4.1. Introduction
  - 17.9.4.2. Market Analysis and Forecast, by Market Taxonomy
    - 17.9.4.2.1. By Drug Coating
    - 17.9.4.2.2. By Indication
    - 17.9.4.2.3. By Artery Type
    - 17.9.4.2.4. By End User
- 17.9.5. Spain Market Analysis
  - 17.9.5.1. Introduction
  - 17.9.5.2. Market Analysis and Forecast, by Market Taxonomy
    - 17.9.5.2.1. By Drug Coating
    - 17.9.5.2.2. By Indication
    - 17.9.5.2.3. By Artery Type
    - 17.9.5.2.4. By End User
- 17.9.6. BENELUX Market Analysis
  - 17.9.6.1. Introduction
  - 17.9.6.2. Market Analysis and Forecast, by Market Taxonomy
    - 17.9.6.2.1. By Drug Coating
    - 17.9.6.2.2. By Indication
    - 17.9.6.2.3. By Artery Type
    - 17.9.6.2.4. By End User
- 17.9.7. Russia Market Analysis
  - 17.9.7.1. Introduction
  - 17.9.7.2. Market Analysis and Forecast, by Market Taxonomy
    - 17.9.7.2.1. By Drug Coating
    - 17.9.7.2.2. By Indication
    - 17.9.7.2.3. By Artery Type
    - 17.9.7.2.4. By End User
- 17.9.8. Nordic Countries Market Analysis
  - 17.9.8.1. Introduction
  - 17.9.8.2. Market Analysis and Forecast, by Market Taxonomy
    - 17.9.8.2.1. By Drug Coating
    - 17.9.8.2.2. By Indication
    - 17.9.8.2.3. By Artery Type
    - 17.9.8.2.4. By End User

18. East Asia Market Analysis 2019-2023 and Forecast 2024-2033

18.1. Introduction
18.2. Historical Market End User (US$ Mn) Analysis, by Market Taxonomy, 2019-2023
18.3. Current and Future Market Value (US$ Mn) Volume (Units) Analysis and Forecast, by Market Taxonomy, 2024-2033
- 18.3.1. By Country
  - 18.3.1.1. China
  - 18.3.1.2. Japan
  - 18.3.1.3. South Korea
- 18.3.2. By Drug Coating
- 18.3.3. By Indication
- 18.3.4. By Artery Type
- 18.3.5. By End User
18.4. Market Attractiveness Analysis
- 18.4.1. By Country
- 18.4.2. By Drug Coating
- 18.4.3. By Indication
- 18.4.4. By Artery Type
- 18.4.5. By End User
18.5. PESTLE Analysis
18.6. Market Trends
18.7. Key Market Participants - Intensity Mapping
18.8. Drivers and Restraints - Impact Analysis
18.9. Country Level Analysis & Forecast
- 18.9.1. China Market Analysis
  - 18.9.1.1. Introduction
  - 18.9.1.2. Market Analysis and Forecast, by Market Taxonomy
    - 18.9.1.2.1. By Drug Coating
    - 18.9.1.2.2. By Indication
    - 18.9.1.2.3. By Artery Type
    - 18.9.1.2.4. By End User
- 18.9.2. Japan Market Analysis
  - 18.9.2.1. Introduction
  - 18.9.2.2. Market Analysis and Forecast, by Market Taxonomy
    - 18.9.2.2.1. By Drug Coating
    - 18.9.2.2.2. By Indication
    - 18.9.2.2.3. By Artery Type
    - 18.9.2.2.4. By End User
- 18.9.3. South Korea Market Analysis
  - 18.9.3.1. Introduction
  - 18.9.3.2. Market Analysis and Forecast, by Market Taxonomy
    - 18.9.3.2.1. By Drug Coating
    - 18.9.3.2.2. By Indication
    - 18.9.3.2.3. By Artery Type
    - 18.9.3.2.4. By End User

19. South Asia Market Analysis 2019-2023 and Forecast 2024-2033

19.1. Introduction
19.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis, by Market Taxonomy, 2019-2023
19.3. Current and Future Market Value (US$ Mn) Volume (Units) Analysis and Forecast, by Market Taxonomy, 2024-2033
- 19.3.1. By Country
  - 19.3.1.1. India
  - 19.3.1.2. Indonesia
  - 19.3.1.3. Malaysia
  - 19.3.1.4. Thailand
  - 19.3.1.5. Rest of South Asia
- 19.3.2. By Drug Coating
- 19.3.3. By Indication
- 19.3.4. By Artery Type
- 19.3.5. By End User
19.4. Market Attractiveness Analysis
- 19.4.1. By Country
- 19.4.2. By Drug Coating
- 19.4.3. By Indication
- 19.4.4. By Artery Type
- 19.4.5. By End User
19.5. PESTLE Analysis
19.6. Market Trends
19.7. Key Market Participants - Intensity Mapping
19.8. Drivers and Restraints - Impact Analysis
19.9. Country Level Analysis & Forecast
- 19.9.1. India Market Analysis
  - 19.9.1.1. Introduction
  - 19.9.1.2. Market Analysis and Forecast, by Market Taxonomy
    - 19.9.1.2.1. By Drug Coating
    - 19.9.1.2.2. By Indication
    - 19.9.1.2.3. By Artery Type
    - 19.9.1.2.4. By End User
- 19.9.2. Indonesia Market Analysis
  - 19.9.2.1. Introduction
  - 19.9.2.2. Market Analysis and Forecast, by Market Taxonomy
    - 19.9.2.2.1. By Drug Coating
    - 19.9.2.2.2. By Indication
    - 19.9.2.2.3. By Artery Type
    - 19.9.2.2.4. By End User
- 19.9.3. Malaysia Market Analysis
  - 19.9.3.1. Introduction
  - 19.9.3.2. Market Analysis and Forecast, by Market Taxonomy
    - 19.9.3.2.1. By Drug Coating
    - 19.9.3.2.2. By Indication
    - 19.9.3.2.3. By Artery Type
    - 19.9.3.2.4. By End User
- 19.9.4. Thailand Market Analysis
  - 19.9.4.1. Introduction
  - 19.9.4.2. Market Analysis and Forecast, by Market Taxonomy
    - 19.9.4.2.1. By Drug Coating
    - 19.9.4.2.2. By Indication
    - 19.9.4.2.3. By Artery Type
    - 19.9.4.2.4. By End User

20. Oceania Market 2019-2023 and Forecast 2024-2033

20.1. Introduction
20.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis, by Market Taxonomy, 2019-2023
20.3. Current and Future Market Value (US$ Mn) Volume (Units) Analysis and Forecast, by Market Taxonomy, 2024-2033
- 20.3.1. By Country
  - 20.3.1.1. Australia
  - 20.3.1.2. New Zealand
- 20.3.2. By Drug Coating
- 20.3.3. By Indication
- 20.3.4. By Artery Type
- 20.3.5. By End User
20.4. Market Attractiveness Analysis
- 20.4.1. By Country
- 20.4.2. By Drug Coating
- 20.4.3. By Indication
- 20.4.4. By Artery Type
- 20.4.5. By End User
20.5. PESTLE Analysis
20.6. Market Trends
20.7. Key Market Participants - Intensity Mapping
20.8. Drivers and Restraints - Impact Analysis
20.9. Country Level Analysis & Forecast
- 20.9.1. Australia Market Analysis
  - 20.9.1.1. Introduction
  - 20.9.1.2. Market Analysis and Forecast, by Market Taxonomy
    - 20.9.1.2.1. By Drug Coating
    - 20.9.1.2.2. By Indication
    - 20.9.1.2.3. By Artery Type
    - 20.9.1.2.4. By End User
- 20.9.2. New Zealand Market Analysis
  - 20.9.2.1. Introduction
  - 20.9.2.2. Market Analysis and Forecast, by Market Taxonomy
    - 20.9.2.2.1. By Drug Coating
    - 20.9.2.2.2. By Indication
    - 20.9.2.2.3. By Artery Type
    - 20.9.2.2.4. By End User

21. Middle East and Africa (MEA) Market Analysis 2019-2023 and Forecast 2024-2033

21.1. Introduction
21.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis, by Market Taxonomy, 2019-2023
21.3. Current and Future Market Value (US$ Mn) Volume (Units) Analysis and Forecast, by Market Taxonomy, 2024-2033
- 21.3.1. By Country
  - 21.3.1.1. GCC Countries
  - 21.3.1.2. Turkey
  - 21.3.1.3. Israel
  - 21.3.1.4. South Africa
  - 21.3.1.5. North Africa
  - 21.3.1.6. Rest of Middle East and Africa
- 21.3.2. By Drug Coating
- 21.3.3. By Indication
- 21.3.4. By Artery Type
- 21.3.5. By End User
21.4. Market Attractiveness Analysis
- 21.4.1. By Country
- 21.4.2. By Drug Coating
- 21.4.3. By Indication
- 21.4.4. By Artery Type
- 21.4.5. By End User
21.5. PESTLE Analysis
21.6. Market Trends
21.7. Key Market Participants - Intensity Mapping
21.8. Drivers and Restraints - Impact Analysis
21.9. Country Level Analysis & Forecast
- 21.9.1. GCC Countries Market Analysis
  - 21.9.1.1. Introduction
  - 21.9.1.2. Market Analysis and Forecast, by Market Taxonomy
    - 21.9.1.2.1. By Drug Coating
    - 21.9.1.2.2. By Indication
    - 21.9.1.2.3. By Artery Type
    - 21.9.1.2.4. By End User
- 21.9.2. Turkey Market Analysis
  - 21.9.2.1. Introduction
  - 21.9.2.2. Market Analysis and Forecast, by Market Taxonomy
    - 21.9.2.2.1. By Drug Coating
    - 21.9.2.2.2. By Indication
    - 21.9.2.2.3. By Artery Type
    - 21.9.2.2.4. By End User
- 21.9.3. Israel Africa Market Analysis
  - 21.9.3.1. Introduction
  - 21.9.3.2. Market Analysis and Forecast, by Market Taxonomy
    - 21.9.3.2.1. By Drug Coating
    - 21.9.3.2.2. By Indication
    - 21.9.3.2.3. By Artery Type
    - 21.9.3.2.4. By End User
- 21.9.4. South Africa Market Analysis
  - 21.9.4.1. Introduction
  - 21.9.4.2. Market Analysis and Forecast, by Market Taxonomy
    - 21.9.4.2.1. By Drug Coating
    - 21.9.4.2.2. By Indication
    - 21.9.4.2.3. By Artery Type
    - 21.9.4.2.4. By End User
- 21.9.5. North Africa Market Analysis
  - 21.9.5.1. Introduction
  - 21.9.5.2. Market Analysis and Forecast, by Market Taxonomy
    - 21.9.5.2.1. By Drug Coating
    - 21.9.5.2.2. By Indication
    - 21.9.5.2.3. By Artery Type
    - 21.9.5.2.4. By End User

22. Market Structure Analysis

22.1. Market Analysis, by Tier of Companies
22.2. Market Share Analysis of Top Players
22.3. Market Presence Analysis

23. Competition Analysis

23.1. Competition Dashboard
23.2. Branding and Promotional Strategies, By Manufacturers
23.3. Key Development Analysis
23.4. Competition Deep Dive
- 23.4.1. Abbott Laboratories
  - 23.4.1.1. Overview
  - 23.4.1.2. Product Portfolio
  - 23.4.1.3. Sales Footprint
  - 23.4.1.4. Key Financials
  - 23.4.1.5. SWOT Analysis
  - 23.4.1.6. Key Developments
  - 23.4.1.7. Strategy Overview
    - 23.4.1.7.1. Marketing Strategy
    - 23.4.1.7.2. Product Strategy
    - 23.4.1.7.3. Channel Strategy
- 23.4.2. Boston Scientific Corporation
  - 23.4.2.1. Overview
  - 23.4.2.2. Product Portfolio
  - 23.4.2.3. Sales Footprint
  - 23.4.2.4. Key Financials
  - 23.4.2.5. SWOT Analysis
  - 23.4.2.6. Key Developments
  - 23.4.2.7. Strategy Overview
    - 23.4.2.7.1. Marketing Strategy
    - 23.4.2.7.2. Product Strategy
    - 23.4.2.7.3. Channel Strategy
- 23.4.3. Cook Medical Inc.
  - 23.4.3.1. Overview
  - 23.4.3.2. Product Portfolio
  - 23.4.3.3. Sales Footprint
  - 23.4.3.4. Key Financials
  - 23.4.3.5. SWOT Analysis
  - 23.4.3.6. Key Developments
  - 23.4.3.7. Strategy Overview
    - 23.4.3.7.1. Marketing Strategy
    - 23.4.3.7.2. Product Strategy
    - 23.4.3.7.3. Channel Strategy
- 23.4.4. MicroPort Scientific Corporation (Endovastec(TM))
  - 23.4.4.1. Overview
  - 23.4.4.2. Product Portfolio
  - 23.4.4.3. Sales Footprint
  - 23.4.4.4. Key Financials
  - 23.4.4.5. SWOT Analysis
  - 23.4.4.6. Key Developments
  - 23.4.4.7. Strategy Overview
    - 23.4.4.7.1. Marketing Strategy
    - 23.4.4.7.2. Product Strategy
    - 23.4.4.7.3. Channel Strategy
- 23.4.5. Medtronic Plc.
  - 23.4.5.1. Overview
  - 23.4.5.2. Product Portfolio
  - 23.4.5.3. Sales Footprint
  - 23.4.5.4. Key Financials
  - 23.4.5.5. SWOT Analysis
  - 23.4.5.6. Key Developments
  - 23.4.5.7. Strategy Overview
    - 23.4.5.7.1. Marketing Strategy
    - 23.4.5.7.2. Product Strategy
    - 23.4.5.7.3. Channel Strategy
- 23.4.6. Cardinal Health, Inc.
  - 23.4.6.1. Overview
  - 23.4.6.2. Product Portfolio
  - 23.4.6.3. Sales Footprint
  - 23.4.6.4. Key Financials
  - 23.4.6.5. SWOT Analysis
  - 23.4.6.6. Key Developments
  - 23.4.6.7. Strategy Overview
    - 23.4.6.7.1. Marketing Strategy
    - 23.4.6.7.2. Product Strategy
    - 23.4.6.7.3. Channel Strategy
- 23.4.7. B. Braun Melsungen AG
  - 23.4.7.1. Overview
  - 23.4.7.2. Product Portfolio
  - 23.4.7.3. Sales Footprint
  - 23.4.7.4. Key Financials
  - 23.4.7.5. SWOT Analysis
  - 23.4.7.6. Key Developments
  - 23.4.7.7. Strategy Overview
    - 23.4.7.7.1. Marketing Strategy
    - 23.4.7.7.2. Product Strategy
    - 23.4.7.7.3. Channel Strategy
- 23.4.8. BIOTRONIK SE & Co. KG
  - 23.4.8.1. Overview
  - 23.4.8.2. Product Portfolio
  - 23.4.8.3. Sales Footprint
  - 23.4.8.4. Key Financials
  - 23.4.8.5. SWOT Analysis
  - 23.4.8.6. Key Developments
  - 23.4.8.7. Strategy Overview
    - 23.4.8.7.1. Marketing Strategy
    - 23.4.8.7.2. Product Strategy
    - 23.4.8.7.3. Channel Strategy
- 23.4.9. Becton, Dickinson and Company
  - 23.4.9.1. Overview
  - 23.4.9.2. Product Portfolio
  - 23.4.9.3. Sales Footprint
  - 23.4.9.4. Key Financials
  - 23.4.9.5. SWOT Analysis
  - 23.4.9.6. Key Developments
  - 23.4.9.7. Strategy Overview
    - 23.4.9.7.1. Marketing Strategy
    - 23.4.9.7.2. Product Strategy
    - 23.4.9.7.3. Channel Strategy
- 23.4.10. W. L. Gore & Associates Inc.
  - 23.4.10.1. Overview
  - 23.4.10.2. Product Portfolio
  - 23.4.10.3. Sales Footprint
  - 23.4.10.4. Key Financials
  - 23.4.10.5. SWOT Analysis
  - 23.4.10.6. Key Developments
  - 23.4.10.7. Strategy Overview
    - 23.4.10.7.1. Marketing Strategy
    - 23.4.10.7.2. Product Strategy
    - 23.4.10.7.3. Channel Strategy
- 23.4.11. Getinge AB
  - 23.4.11.1. Overview
  - 23.4.11.2. Product Portfolio
  - 23.4.11.3. Sales Footprint
  - 23.4.11.4. Key Financials
  - 23.4.11.5. SWOT Analysis
  - 23.4.11.6. Key Developments
  - 23.4.11.7. Strategy Overview
    - 23.4.11.7.1. Marketing Strategy
    - 23.4.11.7.2. Product Strategy
    - 23.4.11.7.3. Channel Strategy
- 23.4.12. Terumo Corp
  - 23.4.12.1. Overview
  - 23.4.12.2. Product Portfolio
  - 23.4.12.3. Sales Footprint
  - 23.4.12.4. Key Financials
  - 23.4.12.5. SWOT Analysis
  - 23.4.12.6. Key Developments
  - 23.4.12.7. Strategy Overview
    - 23.4.12.7.1. Marketing Strategy
    - 23.4.12.7.2. Product Strategy
    - 23.4.12.7.3. Channel Strategy
- 23.4.13. Kyoto Medical Planning Co Ltd
  - 23.4.13.1. Overview
  - 23.4.13.2. Product Portfolio
  - 23.4.13.3. Sales Footprint
  - 23.4.13.4. Key Financials
  - 23.4.13.5. SWOT Analysis
  - 23.4.13.6. Key Developments
  - 23.4.13.7. Strategy Overview
    - 23.4.13.7.1. Marketing Strategy
    - 23.4.13.7.2. Product Strategy
    - 23.4.13.7.3. Channel Strategy
- 23.4.14. iVascular S.L.U
  - 23.4.14.1. Overview
  - 23.4.14.2. Product Portfolio
  - 23.4.14.3. Sales Footprint
  - 23.4.14.4. Key Financials
  - 23.4.14.5. SWOT Analysis
  - 23.4.14.6. Key Developments
  - 23.4.14.7. Strategy Overview
    - 23.4.14.7.1. Marketing Strategy
    - 23.4.14.7.2. Product Strategy
    - 23.4.14.7.3. Channel Strategy
- 23.4.15. AMG International GmbH
  - 23.4.15.1. Overview
  - 23.4.15.2. Product Portfolio
  - 23.4.15.3. Sales Footprint
  - 23.4.15.4. Key Financials
  - 23.4.15.5. SWOT Analysis
  - 23.4.15.6. Key Developments
  - 23.4.15.7. Strategy Overview
    - 23.4.15.7.1. Marketing Strategy
    - 23.4.15.7.2. Product Strategy
    - 23.4.15.7.3. Channel Strategy
- 23.4.16. ENDOCOR GmbH
  - 23.4.16.1. Overview
  - 23.4.16.2. Product Portfolio
  - 23.4.16.3. Sales Footprint
  - 23.4.16.4. Key Financials
  - 23.4.16.5. SWOT Analysis
  - 23.4.16.6. Key Developments
  - 23.4.16.7. Strategy Overview
    - 23.4.16.7.1. Marketing Strategy
    - 23.4.16.7.2. Product Strategy
    - 23.4.16.7.3. Channel Strategy
- 23.4.17. Meril Life Sciences Pvt. Ltd.
  - 23.4.17.1. Overview
  - 23.4.17.2. Product Portfolio
  - 23.4.17.3. Sales Footprint
  - 23.4.17.4. Key Financials
  - 23.4.17.5. SWOT Analysis
  - 23.4.17.6. Key Developments
  - 23.4.17.7. Strategy Overview
    - 23.4.17.7.1. Marketing Strategy
    - 23.4.17.7.2. Product Strategy
    - 23.4.17.7.3. Channel Strategy
- 23.4.18. Nano Therapeutics Pvt Ltd
  - 23.4.18.1. Overview
  - 23.4.18.2. Product Portfolio
  - 23.4.18.3. Sales Footprint
  - 23.4.18.4. Key Financials
  - 23.4.18.5. SWOT Analysis
  - 23.4.18.6. Key Developments
  - 23.4.18.7. Strategy Overview
    - 23.4.18.7.1. Marketing Strategy
    - 23.4.18.7.2. Product Strategy
    - 23.4.18.7.3. Channel Strategy
- 23.4.19. Koninklijke Philips N.V.
  - 23.4.19.1. Overview
  - 23.4.19.2. Product Portfolio
  - 23.4.19.3. Sales Footprint
  - 23.4.19.4. Key Financials
  - 23.4.19.5. SWOT Analysis
  - 23.4.19.6. Key Developments
  - 23.4.19.7. Strategy Overview
    - 23.4.19.7.1. Marketing Strategy
    - 23.4.19.7.2. Product Strategy
    - 23.4.19.7.3. Channel Strategy
- 23.4.20. REVA Medical
  - 23.4.20.1. Overview
  - 23.4.20.2. Product Portfolio
  - 23.4.20.3. Sales Footprint
  - 23.4.20.4. Key Financials
  - 23.4.20.5. SWOT Analysis
  - 23.4.20.6. Key Developments
  - 23.4.20.7. Strategy Overview
    - 23.4.20.7.1. Marketing Strategy
    - 23.4.20.7.2. Product Strategy
    - 23.4.20.7.3. Channel Strategy